MHUA vs. INO, PYPD, APT, QTI, DXR, ICCM, PSTV, MLSS, GUTS, and EDAP
Should you be buying Meihua International Medical Technologies stock or one of its competitors? The main competitors of Meihua International Medical Technologies include Inovio Pharmaceuticals (INO), PolyPid (PYPD), Alpha Pro Tech (APT), QT Imaging (QTI), Daxor (DXR), IceCure Medical (ICCM), Plus Therapeutics (PSTV), Milestone Scientific (MLSS), Fractyl Health (GUTS), and EDAP TMS (EDAP). These companies are all part of the "medical equipment" industry.
Meihua International Medical Technologies vs. Its Competitors
Meihua International Medical Technologies (NASDAQ:MHUA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.
1.2% of Meihua International Medical Technologies shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 66.6% of Meihua International Medical Technologies shares are owned by company insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Meihua International Medical Technologies' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.
Meihua International Medical Technologies has higher revenue and earnings than Inovio Pharmaceuticals.
Inovio Pharmaceuticals has a consensus price target of $8.80, suggesting a potential upside of 348.98%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Meihua International Medical Technologies.
Meihua International Medical Technologies has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Meihua International Medical Technologies. MarketBeat recorded 4 mentions for Inovio Pharmaceuticals and 1 mentions for Meihua International Medical Technologies. Inovio Pharmaceuticals' average media sentiment score of 0.84 beat Meihua International Medical Technologies' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
Summary
Inovio Pharmaceuticals beats Meihua International Medical Technologies on 8 of the 13 factors compared between the two stocks.
Get Meihua International Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHUA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MHUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Meihua International Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:MHUA) was last updated on 8/24/2025 by MarketBeat.com Staff
MarketBeat All Access